Jemperli (Dostarlimab)

Jemperli (Dostarlimab) is an immune checkpoint inhibitor designed to empower the body’s immune system to combat certain types of cancer. As a PD-1 blocking antibody, Jemperli selectively binds to the PD-1 receptor on T cells, enhancing the body’s natural defenses to detect and fight cancer cells.

Why Choose Jemperli (Dostarlimab)?

• Targeted Action: Jemperli specifically targets the PD-1 pathway, a crucial mechanism that tumors use to evade the immune system.
• Enhanced Immune Response: By inhibiting this pathway, Dostarlimab helps restore the immune system’s ability to detect and destroy cancer cells.
• Clinically Proven: Demonstrated effectiveness in patients with mismatch repair deficient (dMMR) endometrial cancer, providing new hope for those with few treatment options.

How to Use Jemperli (Dostarlimab)?

• Administration: Jemperli (Dostarlimab) is administered as an intravenous infusion, typically given over 30 minutes. The treatment regimen often depends on the patient’s type of cancer, stage, and overall health.
• Dosage: The standard dosage regimen for Jemperli involves an initial phase of treatment every three weeks, followed by a maintenance phase every six weeks. The exact dosage and treatment schedule should be determined by a healthcare provider based on the individual patient’s medical condition and response to therapy.
• Monitoring: Patients receiving Jemperli should be closely monitored by their healthcare provider for the duration of the treatment. Regular assessments may be required to check the effectiveness of the therapy and to identify any potential side effects.

Important Safety Information about Jemperli

• Use in Specific Populations: Jemperli’s safety and effectiveness in pediatric patients have not been established. Pregnant and breastfeeding women should discuss potential risks with their healthcare provider, as Jemperli can harm a developing fetus or newborn.
• Drug Interactions: Patients should inform their healthcare provider about all medications they are taking, as Jemperli can interact with other drugs, potentially leading to increased toxicity or reduced effectiveness.
• Infections: Jemperli can increase the risk of infections, some of which may be serious. Patients should be monitored for signs of infection and treated promptly.

Fact Table for Jemperli

Common Side Effects of Jemperli

Like all medications, Jemperli (Dostarlimab) can cause side effects, although not everybody gets them. Understanding these side effects can help you use this medication safely and effectively.

• Fatigue
• Nausea
• Diarrhea
• Anemia

If you experience any side effects, discuss them with your healthcare provider. They can offer advice and may adjust your treatment if necessary. Report any severe or unexpected side effects immediately.

How Can You Buy Jemperli (Dostarlimab)?

You can order Jemperli (Dostarlimab) using these methods on our website:

1. Order Online
2. Order by Phone
3. Order by Fax
4. Order your refills

Visit our How to order page.

FAQs